Biogen Forecast, price target & analysts
Biogen Target price 2026 - Analyst rating & recommendation
Biogen Classifications & Recommendation
Biogen Price Target
| Target Price | $241.74 |
| Price | $227.60 |
| Potential |
6.21%
register free of charge
|
| Number of Estimates | 34 |
|
34 Analysts have issued a price target Biogen 2027 .
The average Biogen target price is $241.74.
This is
6.21%
register free of charge
$315.00
38.40%
register free of charge
$166.65
26.78%
register free of charge
|
|
| A rating was issued by 43 analysts: 30 Analysts recommend Biogen to buy, 12 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2027 of
6.21%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 9.89 | 10.65 |
| 2.22% | 7.71% | |
| EBITDA Margin | 33.36% | 27.55% |
| 6.26% | 17.42% | |
| Net Margin | 13.07% | 17.51% |
| 22.51% | 33.95% |
38 Analysts have issued a sales forecast Biogen 2026 . The average Biogen sales estimate is
This results in the following potential growth metrics:
19 Analysts have issued an Biogen EBITDA forecast 2026. The average Biogen EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
39 Biogen Analysts have issued a net profit forecast 2026. The average Biogen net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 8.79 | 12.63 |
| 21.45% | 43.69% | |
| P/E | 18.03 | |
| EV/Sales | 3.80 |
39 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is
This results in the following potential growth metrics and future valuations:
Current Biogen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HSBC |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Sep 03 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Aug 04 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HSBC:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Sep 03 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Aug 04 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
